Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 7Recruiting 7Completed 5Terminated 2Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 11Other hematologic neoplasm 9Breast 4Myeloid 3Plasma cell 2Tumor-Agnostic 1Thoracic 1Genitourinary 1Gastrointestinal 1Classical hematology 1

Conditions

Multiple Myeloma 292Lymphoma 45Recurrence 31Neoplasms, Plasma Cell 28Hematologic Neoplasms 25Smoldering Multiple Myeloma 20Lymphoma, Non-Hodgkin 20Neoplasms 13Leukemia, Lymphocytic, Chronic, B-Cell 11Myelodysplastic Syndromes 10Leukemia 10Immunoglobulin Light-chain Amyloidosis 10Leukemia, Myeloid, Acute 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Myeloproliferative Disorders 8Hodgkin Disease 8Waldenstrom Macroglobulinemia 7Lymphoma, Mantle-Cell 6Prostatic Neoplasms 5Paraproteinemias 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Breast Neoplasms 5Lymphoproliferative Disorders 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Hematologic Diseases 4Colorectal Neoplasms 4Anemia, Refractory, with Excess of Blasts 4Anemia, Aplastic 4

Interventions

isatuximab 1fludarabine phosphate 1Whole-Body Irradiation 1Sirolimus 1Mycophenolic Acid 1Melphalan 1Lenalidomide 1Dexamethasone 1Cyclophosphamide 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasm, Residual × Plasma cell × Clear all
NCT03192397 2026-04-14

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
35 enrolled 19 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Graft vs Host Disease, Hodgkin Disease, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

NCT05690984 2026-03-16

EMAT

Medical College of Wisconsin

Phase 2 Active not recruiting
30 enrolled
Plasma cell

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡